4.2 Article

The Treatment of HIV-Associated Nephropathy

期刊

ADVANCES IN CHRONIC KIDNEY DISEASE
卷 17, 期 1, 页码 59-71

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ackd.2009.08.013

关键词

Antiretroviral therapy; HIV-associated nephropathy; Angiotensin-converting enzyme inhibitors; Prednisone; CKD

资金

  1. NIH [AI36219, AI25879]
  2. NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025879, P30AI036219] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Antiretroviral therapy (ART) preserves kidney function in patients with human immunodeficiency virus (HIV)-associated nephropathy (HIVAN). Emerging data also document substantial renal benefits of ART in the general HIV-infected population, which is associated in part with suppression of HIV-1 viral replication. The extent to which the response to ART differs in persons with HIVAN compared with those with other HIV-associated kidney disorders is unknown. Beneficial effects of corticosteroids and angiotensin-converting enzyme inhibitors on kidney function also are suggested by retrospective cohort studies and uncontrolled trials of patients with HIVAN. Underexposure to ART or inadequate ART dosing in HIV-infected patients with CKD may curtail the optimal benefits that may be derived from this therapy. (C) 2010 by the National Kidney Foundation, Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据